David Cundey, MD
Cardiovascular Disease · Aiken, SCNPI 1952487324
Payments from drug & device makers
Across 220 payments — averaging $17.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$626
- Pfizer$473
- Amgen$328
- Abbott$240
- Johnson & Johnson$230
- Boston Scientific$209
- plus $2K from 34 others
What the payments were for
- Consulting fees$150%
- Food & beverage$3,746100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 40 | $626 |
| Pfizer | 28 | $473 |
| Amgen | 24 | $328 |
| Abbott | 12 | $240 |
| Johnson & Johnson | 20 | $230 |
| Boston Scientific | 7 | $209 |
| Inari Medical, Inc. | 5 | $185 |
| Sanofi-aventis U.S. LLC | 10 | $159 |
| Abiomed | 3 | $112 |
| Astellas Pharma US Inc | 6 | $109 |
| E.r. Squibb & Sons, L.L.C. | 6 | $98 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $91 |
| Merck | 5 | $85 |
| Medtronic(2 entities) | 5 | $83 |
| Novo Nordisk | 3 | $69 |
| Daiichi Sankyo Inc. | 3 | $67 |
| Boehringer Ingelheim | 4 | $64 |
| Arbor Pharmaceuticals, Inc. | 4 | $48 |
| Davol Inc. | 1 | $46 |
| United Therapeutics Corporation | 2 | $39 |
| Lundbeck LLC | 2 | $37 |
| Cvrx, Inc. | 3 | $37 |
| Lantheus Medical Imaging, Inc. | 2 | $35 |
| Shockwave Medical, Inc | 1 | $32 |
| Biotronik Inc. | 2 | $31 |
| AstraZeneca | 2 | $27 |
| Stryker | 1 | $17 |
| Solventum Corporation | 1 | $17 |
| Edwards Lifesciences | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Chiesi USA, Inc. | 1 | $15 |
| Cook Medical LLC | 1 | $15 |
| Itamar Medical Inc | 1 | $15 |
| Bayer | 1 | $15 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $14 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Vifor Pharma, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
| Baylis Medical Company Inc | 1 | $12 |
How this compares
$3,761 in reported general payments places this provider in the 45th percentile of 257 cardiovascular disease providers in South Carolina.
See all cardiovascular disease providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 837 | $771,421 |
| VyndamaxTafamidis | 13 | $290,320 |
| EntrestoSacubitril/Valsartan | 233 | $265,592 |
| XareltoRivaroxaban | 106 | $88,656 |
| JardianceEmpagliflozin | 75 | $83,452 |
| FarxigaDapagliflozin Propanediol | 59 | $47,375 |
| BrilintaTicagrelor | 57 | $42,771 |
| Repatha SureclickEvolocumab | 32 | $32,807 |
| MultaqDronedarone Hcl | 17 | $18,028 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 45 | $14,444 |
| EdarbiAzilsartan Medoxomil | 15 | $10,678 |
| Ranolazine ErRanolazine | 120 | $9,156 |
| NexletolBempedoic Acid | 17 | $6,940 |
| Atorvastatin Calcium | 637 | $6,816 |
| Metoprolol Succinate | 448 | $6,557 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $473 | $1,061,740850 claims |
| NovartisEntresto | $626 | $265,592233 claims |
| AstraZenecaFarxiga, Brilinta | $27 | $90,146116 claims |
| Johnson & JohnsonXarelto | $230 | $88,656106 claims |
| Boehringer IngelheimJardiance | $64 | $83,45275 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $48 | $25,12160 claims |
| Sanofi-aventis U.S. LLCMultaq | $159 | $18,02817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 257 cardiovascular disease providers in South Carolina.
Other cardiovascular disease in Aiken
- Gregory EavesAiken$65K
- Brent McLaurinAnderson$1.1M
- Robert BiedermanCharleston$801K
- James MerriamGreenville$728K
- Vipul ShahLancaster$488K
- Arthur EberlyGreenville$438K
- Gregory SanGreenville$429K
- Naresh MoriRock Hill$408K
- Priya KumarGreenwood$351K
- Dev VazGreenville$257K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.